March 27, 2013 / 1:10 PM / 4 years ago

Aastrom Biosciences ends drug trial, to cut half its workforce

March 27 (Reuters) - Aastrom Biosciences Inc said it would end the late-stage trial of its drug to treat critical limb ischemia - a form of peripheral arterial disease - and cut about half of its workforce.

The company now plans to focus on its experimental treatment for a heart condition called dilated cardiomyopathy, in which the heart becomes weak and cannot pump blood efficiently.

The company has about 71 employees, according to Thomson Reuters data.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below